Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
+0.17 (1.78%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.49 - 9.84
52 week 5.85 - 21.22
Open 9.53
Vol / Avg. 326,942.00/540,336.00
Mkt cap 500.40M
P/E     -
Div/yield     -
EPS -1.42
Shares 52.34M
Beta 1.33
Inst. own 67%
Feb 16, 2016
Q4 2015 Regulus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 15, 2015
Regulus Therapeutics Inc at Guggenheim Boston Healthcare Conference Add to calendar
Nov 10, 2015
Regulus Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 5, 2015
Q3 2015 Regulus Therapeutics Inc Earnings Call - Webcast
Nov 5, 2015
Q3 2015 Regulus Therapeutics Inc Earnings Release
Sep 9, 2015
Regulus Therapeutics Inc at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -697.05% -739.08%
Operating margin -715.55% -743.62%
EBITD margin - -566.05%
Return on average assets -35.51% -38.49%
Return on average equity -40.34% -50.28%
Employees 85 -
CDP Score - -


Suite 210, 3545 John Hopkins Court
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Paul C. Grint M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
David L. Szekeres Chief Business Officer, General Counsel, Corporate Secretary
Age: 41
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 61
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Bruce L A Carter PhD Independent Director
Age: 71
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 54
Bio & Compensation  - Reuters